Biotechnology
IT.OMICS
This company will offer each company or laboratory involved in genomics and proteomics to design and implement its internal information system for the management of "omics" data (raw data from genotyping or phenotypes) and to each research grouping (associating private and/or pubic laboratories) to design, implement and possibly host its computer platform for the exchange and management of its shared "omics" data.
CELLVAX
Based on a technological platform and on our expertise in fields of molecular biology, cellular cultures in primo-culture and in established lines and original animal models, we are able to provide customized services for your laboratory. These services allow to speed up the development of drug candidates in the field of cancerology by reducing cost of development. We are able to test your drug candidates in an original anti-tumoral test: nodule in three dimensional (3D) cell culture which has the advantage of the in vivo cellular architecture and interactions. After this in vitro validation, we propose an original orthotopic tumor model in animals (lung cancer, colon cancer, pancreas cancer, prostate cancer, breast cancer...). This tumor model allows development of tumors comparable to human tumors with formation of metastasis in few weeks. Several models are proposed as well concerning angiogenesis in vitro and in vivo, metastatic potential of your drug candidates for tumor cell dissemination in different organs at distance (intravasation and extravasation). All experimental procedures are conducted under strict confidentiality and with the respect of GLP (good laboratory practice) procedures.
MEDIAM
Mediam is a biotech company specialized in the development of diagnostic, prognostic methods and the treatment of certain orphan diseases such as amyloidal diseases. In two years' time, 10 jobs are expected to be created.
TEREO
Tereo is a company specialized in the field of assistance to clinical assays (tests on new drugs) with investigators (doctors) and promoters. Consultancy and organization services to help set up and carry out clinical studies are offered to companies in the pharmaceutical or agrifood sectors. This company, founded in October 2000 is expected to lead to the creation of about ten jobs.
CELLIAL TECHNOLOGIES
This company develops an in vitro model of a hemato-encephalic barrier so as to determine the aptitude of pharmaceutical molecules to reach the brain or not in record time, as early as in the first stage of the development of a new drug. Currently with a staff of six people, the company demonstrates a potential for 20 jobs and €2.3 million in sales in three years' time.
GENOSCREEN
www.genoscreen.fr
Genoscreen, a company specialized in genomic analysis, offers gene sequencing and genotyping services. The genomic market is truly booming in the fields of health (human genome sequencing, gene therapy, etc.) and agrifood (selection of varieties, GMO detection, etc.).
ENDOTIS PHARMA
Endotis Pharma is an emerging biotechnology company initiated by David BECHARD and Philippe LASSALLE. The company is committed to the research and the development of innovative drugs for the treatment of cancer and acute inflammatory diseases. To achieve its objectives the start-up plans to combine science and technology and relies on the initiation of clinical partnerships and contracts with leading biotech and pharmaceutical firms.
PHARMA C
A company in the process of being set up, Pharma C has taken on the aim of developing drug candidates (Clinical Phase I) in the field of neurogenic inflammation, which is a physiological defence mechanism, following the stimulation of peripheral nerves for which induction and amplification can cause major pathologies of a vascular, respiratory, cutaneous, digestive, pelvic, urinary and articular nature. To be noted is that the originality of this project and subsequently this company lies in the innovative nature of this study (neurogenic inflammation) and in the great hope placed in the treatment of migraines, pain, cystitis, incontinence, arthritis, asthma, rhinitis, bronchiolotis, psoriasis, urticaria and irritable bowel syndrome. PHARMA C is expected to generate, in three, approximately thirty jobs within the Eurasanté Business Park.
ALZHEIMER Project
This concerns the development of new molecular and biological markers of neurodegenerative diseases, particularly Alzheimer’s. The project results from work conducted by Inserm unit U422.
HCBS
This project aims to develop a treatment for infections contracted in hospitals in the form of ready-to-use kits. This project stems from work performed at the Côte d’Opale University.
BIOPUCES
This project aims to enhance and start up companies based on the development of a method of analysis of the structural alterations of the genome by high resolution CGH-Array. This work opens up promising perspectives within the scope of new diagnostic and prognostic solutions of pathologies associated with genome alterations.
COLITE
This project involves enhancement based on the expertise of the Diseases of the Digestive Tract and Nutrition Wards of Professor Desreumaux and the development of proof of concept tools that demonstrate a strong interest on the part of industrial companies, particularly with regard to identifying, validating therapeutic targets and to demonstrating the harmlessness and effectiveness of ‘health food’’ products.
